글로벌 이식형 심장 리듬 관리 시장 – 2031년까지의 산업 동향 및 예측

이식형 심장 리듬 관리 시장 분석 및 규모

이식형 심장 리듬 관리에 대한 글로벌 시장은 심혈관 질환의 유병률 증가, 기술 발전, 인구 고령화와 같은 요인에 의해 주도되어 상당한 성장을 경험하고 있습니다. 세계보건기구(WHO) 데이터에 따르면, 전 세계 사망자의 30% 이상을 차지하는 심혈관 질환은 효과적인 심장 리듬 관리 솔루션에 대한 절실한 필요성을 강조합니다. 이 시장에 크게 기여하는 요인은 전 세계적으로 약 3,350만 명에게 영향을 미치는 심방세동(AFib) 입니다 . 이러한 통계는 심장 질환의 증가하는 부담을 해결하는 데 있어 혁신적인 기술과 고급 솔루션의 중요성을 강조합니다. 제조업체는 이러한 증가하는 수요를 충족하기 위해 비용 효율적이고 최소 침습적 장치를 개발하는 데 중점을 둘 가능성이 높으므로 예측 기간 동안 시장 성장을 촉진합니다.

글로벌 이식형 심장 리듬 관리 시장 규모는 2023년에 186억 2천만 달러로 평가되었으며, 2031년까지 267억 2천만 달러에 도달할 것으로 예상되며, 2024년에서 2031년까지의 예측 기간 동안 CAGR은 4.62%입니다. Data Bridge Market Research에서 큐레이팅한 시장 보고서에는 시장 가치, 성장률, 세분화, 지리적 범위, 주요 업체와 같은 시장 시나리오에 대한 통찰력 외에도 심층 전문가 분석, 환자 역학, 파이프라인 분석, 가격 분석 및 규제 프레임워크도 포함됩니다.

보고 범위 및 시장 세분화       

시장 정의

이식형 심장 리듬 관리(ICRM)는 특정 심장 질환이 있는 개인의 심장의 전기적 활동을 모니터링하고 관리하도록 설계된 일련의 의료 기기 를 말합니다 . 이러한 기기는 신체 내부에 이식되어 필요에 따라 전기적 자극이나 충격을 전달하여 심장의 리듬을 조절하는 데 도움이 됩니다. ICRM 기기에는 심장 근육에 전기 신호를 보내 리듬을 조절하여 규칙적인 심장 박동을 유지하는 데 도움이 되는 페이스메이커와 심장 리듬을 모니터링하고 위험한 부정맥이 감지되면 전기 충격을 전달하여 정상적인 리듬을 회복하는 이식형 심장 박동 제세동기(ICD)가 포함됩니다. 

이식형 심장 리듬 관리 시장 동향

운전자

• 심혈관 질환의 유병률 증가     

전 세계 고령 인구의 증가와 앉아서 생활하는 라이프스타일의 증가는 부정맥과 심부전과 같은 심혈관 질환의 상당한 증가로 이어질 것으로 예상됩니다. 이러한 추세는 이러한 심장 질환을 관리하기 위한 효과적인 솔루션에 대한 필요성이 증가함에 따라 이식형 심장 리듬 관리(ICRM) 기기에 대한 수요를 증가시키고 있습니다. 예를 들어, CDC에 따르면 가장 흔한 유형의 부정맥인 심방세동은 2017년에 미국에서 약 270만~610만 명의 사람들에게 영향을 미친 것으로 추산됩니다. 심혈관 질환의 이러한 유병률 증가는 전 세계적으로 ICRM 기기 채택을 촉진하는 주요 요인입니다.

• ICRM 장치의 기술적 발전

소형화, 리드리스 페이싱 시스템, 무선 통신을 포함한 장치 기술의 지속적인 발전은 ICRM 장치의 효과성과 안전성 벤치마크를 근본적으로 변화시키고 있습니다. 이러한 기술적 진보는 환자 결과를 개선할 뿐만 아니라 이러한 심장 임플란트의 채택률을 자극하고 있습니다. 보다 컴팩트하고 효과적인 장치를 만드는 진전은 환자와 의료 제공자 모두에게 접근성과 매력을 높여 ICRM 시장 확장을 촉진하고 있습니다.

기회

• 리드리스 디바이스 개발

The emergence of leadless pacing systems and other innovative technologies is opening up new pathways for the Implantable Cardiac Rhythm Management (ICRM) market. These cardiac implant devices offer notable advantages, such as a reduced risk of infection and enhanced patient comfort, leading to their increasing adoption among patients and healthcare providers. For instance, in April 2022, Abbott announced that the Aveir single-chamber (VR) leadless pacemaker had obtained approval from the Food and Drug Administration (FDA) for treating patients with slow heart rhythms in the U.S.. This approval marks a significant leap forward in patient care, introducing novel features previously unavailable to patients and their healthcare providers. This evolution of leadless devices is reshaping the landscape of ICRM devices, presenting lucrative opportunities for market players.

• Telemedicine and Remote Monitoring with ICRM Devices

The integration of telemedicine and remote monitoring technologies with ICRM devices is revolutionizing patient care and management. These technologies enable healthcare providers to remotely monitor patients' cardiac activity, leading to early detection of issues and improved patient outcomes. The convenience and efficiency offered by telemedicine and remote monitoring are driving their adoption in the ICRM market, creating new growth prospects for market players.

Restraints/Challenges

• High Cost of ICRM Devices

The excessive cost associated with ICRM devices, including implantation procedures and follow-up care, poses a significant barrier to market growth. This is especially true in developing countries with limited healthcare budgets and infrastructure, where the high cost of these devices can deter patients from opting for them. To overcome this challenge, market players need to focus on developing cost-effective solutions and expanding access to these devices in emerging markets.

• Risks Associated with Implantation

The implantation of ICRM devices comes with inherent risks, such as infection, device malfunction, and lead complications. These risks can deter patients from opting for these devices and impact market growth. To mitigate these risks, healthcare providers need to ensure proper patient selection, implantation techniques, and post-operative care. In addition, ongoing advancements in cardiac implantable devices technology aim to reduce these risks, making ICRM devices safer and more reliable for patients.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In October 2023, MicroPort CRM announced the launch of the ULYS Implantable Cardioverter Defibrillator (ICDs) and the INVICTA defibrillation lead in Japan, enhancing their global product portfolio
• In January 2022, Medtronic plc disclosed that it had obtained approval from Japan's Ministry of Health, Labor and Welfare for both the sale and reimbursement of the Micra AV Transcatheter Pacing System (TPS)

Implantable Cardiac Rhythm Management Market Scope

The market is segmented on the basis of product and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product

• Pacemakers
  • Implantable
  • External
• Defibrillators
  • Implantable Cardioverter Defibrillators (ICD)
    • S-ICD
    • T-ICD
  • External Defibrillator
    • Manual External Defibrillator
    • Automatic External Defibrillator
    • Wearable Cardioverter Defibrillator
• Cardiac Resynchronization Therapy (CRT)
  • CRT-Defibrillator
  • CRT-Pacemakers
• Implantable Loop Recorder

End User

• Hospitals
• Specialty Cardiac Centres
• Ambulatory Surgical Centres
• Others

Implantable Cardiac Rhythm Management Market Regional Analysis/Insights

The market is analyzed and market size insights and trends are provided by country, product, and end user as referenced above.

The countries covered in the market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, rest of Middle East and Africa, Brazil, Argentina, and rest of South America.

North America is expected to dominate the market due to advancements in technology, such as miniaturization and the development of leadless or biocompatible materials, which are key drivers propelling market growth in the region. These technological advancements have enabled the creation of smaller, more efficient devices that are more compatible with the human body. In addition, government regulatory approvals play a crucial role in fostering market growth by ensuring the safety and efficacy of these medical devices.

Asia-Pacific is expected to witness significant growth during the forecast period due to the increasing number of elderly individuals and the growing incidence of cardiac disorders. This demographic shift towards an older population has led to a higher demand for cardiac devices, as age is a significant risk factor for cardiovascular diseases. The rising prevalence of cardiac disorders, including heart failure, arrhythmias, and coronary artery disease, is contributing to the market's growth.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.

Competitive Landscape and Implantable Cardiac Rhythm Management Market Share Analysis

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

Some of the major players operating in the market are:

• Medtronic (U.S.)
• Abbott (U.S.)
• Stryker (U.S.)
• Asahi Kasei Corporation (Japan)
• Boston Scientific Corporation (U.S.)
• Biotronik (Germany)
• Integer Holdings Corporation (U.S.)
• MicroPort Scientific Corporation (China)
• Koninklijke Philips NV(네덜란드)
• ZOLL Medical Corporation (미국)
• 아비오메드(미국)
• 베를린 하트(독일)
• Jarvik Heart, Inc. (미국)
• NIHON KOHDEN CORPORATION (일본)
• 디비브텍 LLC(미국)
• Medicalsystem Co., Ltd. (중국)
• 리바노바 PLC(영국)
• Cardiac Science Corporation (미국)
• 3M(미국)
• 멘티스(스웨덴)

SKU-43617